Ranjit Bindra

Ranjit Bindra

Company: Yale Brain Tumor Center

Job title: Associate Professor, Therapeutic Radiology and Pathology

Bio:

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumorsIn the laboratory, his group recently led a team of four major laboratories at Yale. As a biotech entrepreneur, Dr. Bindra has started several life sciences ventures over the last 10 years. Most recently, he co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment.  

 

which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Building on this discovery, a more recent study in his laboratory was published in Nature Genetics, which highlights the expanding significance of this work: specific tumor-associated mutations induce the aberrant production of citric acid cycle-related metabolites, which drives genetic instability and BRCAness. Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). 

 

As a biotech entrepreneur, Dr. Bindra has started several life sciences ventures over the last 10 yearsMost recently, he co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Cybrexa is led by an experienced business team that has built numerous successful biotech ventures and raised hundreds of millions of dollars in venture capital. 

 

Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center in 2012. 

Seminars:

Utilizing alphalexTM to Empower New Applications and Combinations of Existing DDR Therapies 12:00 pm

Read more

day: Day Two

PARPi’s for BRCAness 9:00 am

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.